Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01034631
Registration number
NCT01034631
Ethics application status
Date submitted
15/12/2009
Date registered
17/12/2009
Date last updated
11/07/2022
Titles & IDs
Public title
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Query!
Scientific title
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Query!
Secondary ID [1]
0
0
HOG GU09-145
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Renal Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Everolimus
Treatment: Drugs - BNC105P
Active Comparator: Combination Arm A: Everolimus + BNC105P - Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
Active Comparator: Sequential Arm B:Everolimus followed by BNC105P Monotherapy - Sequential Arm B: Everolimus 10 mg, 21 day cycle
Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.
Treatment: Drugs: Everolimus
Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
Treatment: Drugs: BNC105P
BNC105P, up to 16 mg/m^2
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus.
Query!
Assessment method [1]
0
0
Phase I
Query!
Timepoint [1]
0
0
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Query!
Primary outcome [2]
0
0
Phase I: Toxicities of BNC105P in Combination With Everolimus.
Query!
Assessment method [2]
0
0
Determine the toxicities of BNC105P in combination with everolimus. Drug-related treatment emergent adverse events by CTCAE grade 2 or greater are reported
Query!
Timepoint [2]
0
0
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Query!
Primary outcome [3]
0
0
Phase II: 6-month Progression Free Survival (PFS) With the Addition of BNC105P to Everolimus.
Query!
Assessment method [3]
0
0
Improvement in 6-month PFS with the addition of BNC105P to everolimus. Progression is defined using RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
Query!
Timepoint [3]
0
0
6 months
Query!
Secondary outcome [1]
0
0
Phase I: Response Rate of BNC105P in Combination With Everolimus.
Query!
Assessment method [1]
0
0
Number of objective responses per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Query!
Timepoint [1]
0
0
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Query!
Secondary outcome [2]
0
0
Geometric Mean Half-life of BNC105 and BNC105P in Combination With Everolimus.
Query!
Assessment method [2]
0
0
Determine the PK Profile for BN105P in combination with everolimus by calculating the geometric mean half-life of BNC105P
Query!
Timepoint [2]
0
0
12 months
Query!
Secondary outcome [3]
0
0
Phase II: Response Rate With Combination Therapy Compared to Everolimus Alone
Query!
Assessment method [3]
0
0
Objective response is defined as a confirmed CR or PR per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Query!
Timepoint [3]
0
0
12 months
Query!
Secondary outcome [4]
0
0
Phase II: Progression Free Survival (PFS) With BNC105P Alone in Patients After Progressing on Everolimus.
Query!
Assessment method [4]
0
0
Median time to progression for arm P participants who crossed over to BNC105P monotherapy after progression. Progression is defined per RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
Query!
Timepoint [4]
0
0
12 months
Query!
Secondary outcome [5]
0
0
Phase II: Adverse Events of Everolimus and BNC105P When Administered as a Combination or Sequential Regimen.
Query!
Assessment method [5]
0
0
Determine adverse events of everolimus and BNC105P when administered as a combination or sequential regimen. Total number of serious and non-serious adverse events for Arm A and Arm B are summarized. Complete adverse event information is supplied in the Adverse Events reporting section.
Query!
Timepoint [5]
0
0
12 months
Query!
Secondary outcome [6]
0
0
Phase II: Overall Survival
Query!
Assessment method [6]
0
0
Determine overall survival probability, up to a maximum of 5 years from registration for protocol therapy.
Query!
Timepoint [6]
0
0
60 months
Query!
Secondary outcome [7]
0
0
Exploratory Objective: Correlation of PFS With Biomarkers
Query!
Assessment method [7]
0
0
Exploratory analysis of serum biomarkers were undertaken to generate a potential signature for response. The correlation with 6 month progression free survival P value for four plasma biomarkers is reported.
Query!
Timepoint [7]
0
0
6 months
Query!
Eligibility
Key inclusion criteria
- Histological or cytological proof of component (any percent) of clear cell RCC (renal
cell carcinoma).
- Metastatic or locally advanced unresectable RCC. NOTE: Prior nephrectomy is not
mandatory.
- Progressive disease after 1-2 prior VEGF-directed tyrosine kinase inhibitors (TKIs).
- Measurable disease according to RECIST and obtained by imaging within 30 days prior to
registration for protocol therapy.
- Written informed consent and HIPAA authorization for release of personal health
information.
- Age > 18 years at the time of consent.
- Females of childbearing potential and males must be willing to use an effective method
of contraception (hormonal or barrier method of birth control; abstinence) from the
time consent is signed until 4 weeks after treatment discontinuation.
- Females of childbearing potential must have a negative pregnancy test within 7 days
prior to registration for protocol therapy.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- No active brain metastases. Patients with neurological symptoms must undergo a head CT
scan or brain MRI to exclude brain metastasis within 30 days prior to registration on
protocol therapy. NOTE: A patient with prior brain metastasis are eligible if they
have completed their radiation treatment for brain metastasis =30 days prior to
registration for protocol therapy, are off steroids, and are asymptomatic.
- No other currently active malignancy.
- No treatment with any investigational agent within 14 days prior to registration for
protocol therapy. NOTE: If treated with investigational agent within 14 days prior to
registration, AE must be resolved back to baseline.
- Prior cancer treatment must be completed at least 14 days prior to registration for
protocol therapy and the patient must have recovered from the acute toxic effects of
the regimen. With the exception of Bevacizumab treatment, which must be completed 30
days prior to registration for protocol therapy.
- Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart
in the study procedure manual (SPM)] allowed if completed within 30 days prior to
registration for protocol therapy.
- Corrected QT interval (QTc) = 450 msec at least 7 days prior to registration for
protocol therapy.
- No clinically significant infections as judged by the treating investigator.
- No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
hepatitis.
- No collecting duct, medullary or sarcomatoid histology.
- No prior treatment with temsirolimus or everolimus in the phase II component of the
study. NOTE: Prior treatment with these agents is permitted in the phase I component
of the study.
- No use of full dose, therapeutic anti-coagulation with warfarin or related
anti-coagulants or unfractionated or low molecular weight heparins.
- No uncontrolled hypertension (BP >150/100mmHg despite full doses of 1
anti-hypertensive medication).
- No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of
registration for protocol therapy.
- No grade 2 or greater peripheral neuropathy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
154
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital: Sydney Cancer Centre - Camperdown
Query!
Recruitment hospital [2]
0
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [3]
0
0
Sydney Adventist Hospital Ltd. - Wahroonga
Query!
Recruitment hospital [4]
0
0
Gallipoli Medical Research Foundation: Greenslopes Private Hospital - Greenslopes
Query!
Recruitment hospital [5]
0
0
Royal Brisbane & Women's Hospital - Herston
Query!
Recruitment hospital [6]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [7]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [8]
0
0
Ashford Cancer Centre - Kurralta Park
Query!
Recruitment hospital [9]
0
0
Gallipoli Medical Research Foundation: Launceston General Hospital - Launceston
Query!
Recruitment hospital [10]
0
0
Peninsula Oncology Centre - Frankston
Query!
Recruitment hospital [11]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [12]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [13]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [4]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [5]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [6]
0
0
4201 - Woolloongabba
Query!
Recruitment postcode(s) [7]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [8]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [9]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [10]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [11]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [12]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [13]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Montana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Hampshire
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Jersey
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Mexico
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Ohio
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oklahoma
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oregon
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Pennsylvania
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Rhode Island
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Tennessee
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Texas
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Wisconsin
Query!
Country [35]
0
0
Singapore
Query!
State/province [35]
0
0
Singapore
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Hoosier Cancer Research Network
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Bionomics Limited
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether BNC105P in combination with/following
everolimus is effective in the treatment of progressive metastatic clear cell renal cell
carcinoma following prior tyrosine kinase inhibitors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01034631
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Thomas Hutson, D.O.
Query!
Address
0
0
Hoosier Cancer Research Network
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01034631
Download to PDF